# Bio-Techne Moat

Status: published. Policy: company-analysis-1.

Bio-Techne has current specialized intellectual property and customer-specific, sole-manufacturer relationships that suggest localized advantages. Their economic breadth and persistence remain insufficiently established for a company-wide moat verdict. Consumables demand supports repeat purchasing indirectly, but purchasing consolidation and low-cost entrants exert disclosed pricing pressure. Contract terms permit price changes in part of the business; demonstrated price realization remains weakly supported. Operating resilience is mixed, and prospective merger benefits do not establish a current advantage.

## switching_costs

Custom diagnostic reagents tailored to customer assays, predominantly supplied through OEM relationships, and existing sole-manufacturer positions indicate customer dependency. Switching friction is plausible, but its cost and effect on customer retention are not quantified.

Durability: Sole-manufacturer dependency appears in both fiscal 2024 and fiscal 2026 disclosures. This supports continuity of the relationship type, without establishing continuity of individual customers or durable protection across the company.

Risks: Customers can consolidate purchasing, seek alternative vendors or redesign assays. Regulatory or manufacturing failures could disrupt customers and undermine these relationships.

Invalidation: The switching-cost hypothesis would weaken materially if customers routinely qualified alternative suppliers without meaningful disruption, custom OEM relationships were lost, or repeat consumables demand persistently deteriorated because of substitution.

Competitors: Not established
## intangible_assets

Granted patents, trade secrets and FDA-cleared products establish existing technical and regulatory assets. Their existence supports differentiation, but does not establish commercially decisive exclusivity or superior economics across the portfolio.

Durability: Protection depends on claim scope, remaining patent life, trade-secret preservation and continued innovation. Neither patent counts nor regulatory clearance establish an exceptional duration of economic protection.

Risks: The issuer acknowledges that intellectual property does not always provide significant competitive advantage. Design-arounds, challenges and increasing competition can erode differentiation.

Invalidation: This hypothesis would fail if important protected products were readily replaced by equivalent alternatives, material claims were invalidated or circumvented, or new introductions failed to sustain commercially relevant differentiation.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm) · 2026-08-24
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm) · 2026-05-06
- [https://www.sec.gov/Archives/edgar/data/842023/000130817925000599/tech014339-def14a.htm](https://www.sec.gov/Archives/edgar/data/842023/000130817925000599/tech014339-def14a.htm) · 2025-09-19
- [https://www.sec.gov/Archives/edgar/data/842023/000155837025011716/tech-20250630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000155837025011716/tech-20250630x10k.htm) · 2025-08-22
- [https://www.sec.gov/Archives/edgar/data/842023/000155837024012430/tech-20240630x10k.htm](https://www.sec.gov/Archives/edgar/data/842023/000155837024012430/tech-20240630x10k.htm) · 2024-08-22
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926010335/tech-20251231x10q.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926010335/tech-20251231x10q.htm) · 2026-02-04
- [https://www.sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_ex99-1.htm](https://www.sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_ex99-1.htm) · 2026-09-23
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812xex99d1.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812xex99d1.htm) · 2026-08-12
- [https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812xex99d2.htm](https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812xex99d2.htm) · 2026-08-12
- [https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/ex99-1.htm](https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/ex99-1.htm) · 2026-06-25
- [https://www.bio-techne.com/terms-and-conditions](https://www.bio-techne.com/terms-and-conditions) · 2026-10-19

[JSON](https://beanvest.com/stock/tech/moat.json)